<p>GRAIL, Inc.（纳斯达克代码：GRAL - 获取免费报告）在周二市场开盘前出现了下跌。该股票之前收于 84.94 美元，但开盘时为 78.62 美元。GRAIL 的股票最后交易价格为 76.19 美元，成交量为 282,585 股。</p>
<h2>分析师评级调整</h2>
<ul>
<li>2025 年表现优于市场的 3 只医疗科技股票</li>
</ul>
<p>一些股票分析师最近对 GRAL 股票发布了报告。Guggenheim 将 GRAIL 的评级从 “中性” 上调至 “买入”，并在 11 月 12 日的研究报告中设定了 100.00 美元的目标价。瑞银集团在 10 月 3 日的报告中对 GRAIL 设定了 75.00 美元的目标价。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 GRAIL 股票的 “卖出（d-）” 评级。最后，加拿大皇家银行将 GRAIL 的目标价从 85.00 美元上调至 105.00 美元，并在周一的研究报告中给予该股票 “买入” 评级。两位分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，GRAIL 目前的共识评级为 “持有”，平均目标价为 75.00 美元。</p>
<p><strong>查看我们关于 GRAL 的最新报告</strong></p>
<h2>GRAIL 股票表现</h2>
<ul>
<li>GRAIL：瞄准 1000 亿美元癌症市场的生物科技股票</li>
</ul>
<p>该公司的市值为 31.1 亿美元，市盈率为-6.85，贝塔值为 4.29。该公司的 50 日移动平均线为 67.81 美元，200 日移动平均线为 48.75 美元。</p>
<p>GRAIL（纳斯达克代码：GRAL - 获取免费报告）在 11 月 12 日最后发布了其财报。该公司报告本季度每股收益为（2.46 美元），超出分析师共识预期的（3.40 美元）0.94 美元。该公司本季度的收入为 3619 万美元，而共识预期为 3383 万美元。GRAIL 的股本回报率为-15.69%，净利润率为-286.43%。平均而言，股票研究分析师预测 GRAIL, Inc.在本年度将发布-15.15 美元的每股收益。</p>
<h2>内部交易活动</h2>
<ul>
<li>战略性买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
<p>在相关消息中，总裁 Joshua J. Ofman 于 10 月 16 日星期四出售了 6114 股该股票。股票以平均价格 82.01 美元出售，总价值为 501,409.14 美元。出售后，总裁直接持有该公司 381,818 股股票，价值约为 31,312,894.18 美元。这代表其持股比例下降了 1.58%。该出售在与证券交易委员会的法律文件中披露，相关信息可在此链接查看。此外，首席执行官 Robert P. Ragusa 于 10 月 15 日星期三出售了 7239 股该公司的股票。股票以平均价格 68.88 美元出售，总交易额为 498,622.32 美元。交易后，首席执行官持有 727,388 股该公司的股票，价值 50,102,485.44 美元。这笔交易代表其持股比例下降了 0.99%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在上个季度共出售了 113,295 股公司股票，价值 7,380,888 美元。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近调整了对该股票的持有。Comerica Bank 在第三季度将其在 GRAIL 的持股比例提高了 59.2%。Comerica Bank 现在拥有 465 股该公司的股票，价值 27,000 美元，此前在上个季度又购买了 173 股。Farther Finance Advisors LLC 在第二季度将其在 GRAIL 的持股比例提高了 768.1%。Farther Finance Advisors LLC 现在拥有 816 股该公司的股票，价值 42,000 美元，此前在上个季度又收购了 722 股。NewEdge Advisors LLC 在第一季度将其在 GRAIL 的持股比例提高了 390.3%。NewEdge Advisors LLC 现在拥有 1760 股该公司的股票，价值 45,000 美元，此前在上个季度又收购了 1401 股。Signaturefd LLC 在第一季度将其在 GRAIL 的持股比例提高了 273.0%。Signaturefd LLC 现在拥有 1876 股该公司的股票，价值 48,000 美元，此前在上个季度又收购了 1373 股。最后，Quarry LP 在第一季度将其在 GRAIL 的持股比例提高了 1965.4%。Quarry LP 现在拥有 2148 股该公司的股票，价值 55,000 美元，此前在上个季度又收购了 2044 股。</p>
<h2>GRAIL 公司简介</h2>
<p>（获取免费报告）</p>
<p>GRAIL, Inc 是一家商业阶段的医疗保健公司，专注于开发早期癌症检测技术。它利用机器学习、软件和自动化技术在早期阶段检测和识别多种致命癌症类型。该公司由 Jeffrey T.创立。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票比 GRAIL 更好</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>为什么 20 秒的飞行测试可能为垂直市场解锁数十亿美元</li>
<li>市值计算器：如何计算市值</li>
<li>3 只适合不安市场的防御性股票</li>
<li>初学者如何阅读股票图表</li>
<li>这 3 只股票正在利用回购来传达市场信心</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 GRAIL 吗？</h2>
<p>在你考虑 GRAIL 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 GRAIL 并不在名单上。</p>
<p>虽然 GRAIL 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看五只股票</p>

GRAL

<p>GRAIL, Inc.（纳斯达克代码：GRAL）股价跳空下跌，开盘价为 78.62 美元，前一交易日收盘价为 84.94 美元，最新交易价为 76.19 美元。分析师的评级意见不一：Guggenheim 将评级上调至 “买入”，目标价为 100 美元；瑞银设定目标价为 75 美元；Weiss Ratings 给予 “卖出” 评级；Canaccord Genuity 将目标价上调至 105 美元。内部人士出售了股份，机构投资者调整了持仓。GRAIL 的目标是早期癌症检测，市值为 31.1 亿美元</p>

<p>GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $84.94, but opened at $78.62. GRAIL shares last traded at $76.19, with a volume of 282,585 shares traded.</p>
<div class="lb-trans"><p>GRAIL, Inc.（纳斯达克代码：GRAL - 获取免费报告）在周二市场开盘前出现了下跌。该股票之前收于 84.94 美元，但开盘时为 78.62 美元。GRAIL 的股票最后交易价格为 76.19 美元，成交量为 282,585 股。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表现优于市场的 3 只医疗科技股票</li>
</ul>
</div><p>A number of equities analysts have recently issued reports on GRAL shares. Guggenheim raised GRAIL from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $100.00 target price for the company in a research note on Wednesday, November 12th. UBS Group set a $75.00 price objective on GRAIL in a report on Friday, October 3rd. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of GRAIL in a report on Wednesday, October 8th. Finally, Canaccord Genuity Group boosted their target price on shares of GRAIL from $85.00 to $105.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, GRAIL presently has a consensus rating of &#34;Hold&#34; and an average target price of $75.00.</p>
<div class="lb-trans"><p>一些股票分析师最近对 GRAL 股票发布了报告。Guggenheim 将 GRAIL 的评级从 “中性” 上调至 “买入”，并在 11 月 12 日的研究报告中设定了 100.00 美元的目标价。瑞银集团在 10 月 3 日的报告中对 GRAIL 设定了 75.00 美元的目标价。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 GRAIL 股票的 “卖出（d-）” 评级。最后，加拿大皇家银行将 GRAIL 的目标价从 85.00 美元上调至 105.00 美元，并在周一的研究报告中给予该股票 “买入” 评级。两位分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，GRAIL 目前的共识评级为 “持有”，平均目标价为 75.00 美元。</p>
</div><p><strong>View Our Latest Report on GRAL</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 GRAL 的最新报告</strong></p>
</div><h2>GRAIL Stock Performance</h2>
<div class="lb-trans"><h2>GRAIL 股票表现</h2>
</div><ul>
<li>GRAIL: Biotech Stock Targeting $100B Cancer Market</li>
</ul>
<div class="lb-trans"><ul>
<li>GRAIL：瞄准 1000 亿美元癌症市场的生物科技股票</li>
</ul>
</div><p>The firm has a market cap of $3.11 billion, a price-to-earnings ratio of -6.85 and a beta of 4.29. The business has a fifty day moving average of $67.81 and a two-hundred day moving average of $48.75.</p>
<div class="lb-trans"><p>该公司的市值为 31.1 亿美元，市盈率为-6.85，贝塔值为 4.29。该公司的 50 日移动平均线为 67.81 美元，200 日移动平均线为 48.75 美元。</p>
</div><p>GRAIL (NASDAQ:GRAL - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($2.46) EPS for the quarter, topping analysts' consensus estimates of ($3.40) by $0.94. The company had revenue of $36.19 million for the quarter, compared to the consensus estimate of $33.83 million. GRAIL had a negative return on equity of 15.69% and a negative net margin of 286.43%. On average, equities research analysts forecast that GRAIL, Inc. will post -15.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>GRAIL（纳斯达克代码：GRAL - 获取免费报告）在 11 月 12 日最后发布了其财报。该公司报告本季度每股收益为（2.46 美元），超出分析师共识预期的（3.40 美元）0.94 美元。该公司本季度的收入为 3619 万美元，而共识预期为 3383 万美元。GRAIL 的股本回报率为-15.69%，净利润率为-286.43%。平均而言，股票研究分析师预测 GRAIL, Inc.在本年度将发布-15.15 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>战略性买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
</div><p>In related news, President Joshua J. Ofman sold 6,114 shares of the stock in a transaction dated Thursday, October 16th. The shares were sold at an average price of $82.01, for a total value of $501,409.14. Following the sale, the president directly owned 381,818 shares of the company's stock, valued at approximately $31,312,894.18. This represents a 1.58% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CEO Robert P. Ragusa sold 7,239 shares of the firm's stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $68.88, for a total transaction of $498,622.32. Following the transaction, the chief executive officer owned 727,388 shares of the company's stock, valued at $50,102,485.44. This trade represents a 0.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 113,295 shares of company stock worth $7,380,888 over the last quarter.</p>
<div class="lb-trans"><p>在相关消息中，总裁 Joshua J. Ofman 于 10 月 16 日星期四出售了 6114 股该股票。股票以平均价格 82.01 美元出售，总价值为 501,409.14 美元。出售后，总裁直接持有该公司 381,818 股股票，价值约为 31,312,894.18 美元。这代表其持股比例下降了 1.58%。该出售在与证券交易委员会的法律文件中披露，相关信息可在此链接查看。此外，首席执行官 Robert P. Ragusa 于 10 月 15 日星期三出售了 7239 股该公司的股票。股票以平均价格 68.88 美元出售，总交易额为 498,622.32 美元。交易后，首席执行官持有 727,388 股该公司的股票，价值 50,102,485.44 美元。这笔交易代表其持股比例下降了 0.99%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在上个季度共出售了 113,295 股公司股票，价值 7,380,888 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. Comerica Bank lifted its stake in GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company's stock valued at $27,000 after buying an additional 173 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of GRAIL by 768.1% in the second quarter. Farther Finance Advisors LLC now owns 816 shares of the company's stock valued at $42,000 after acquiring an additional 722 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of GRAIL by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock valued at $45,000 after acquiring an additional 1,401 shares in the last quarter. Signaturefd LLC boosted its stake in shares of GRAIL by 273.0% during the first quarter. Signaturefd LLC now owns 1,876 shares of the company's stock valued at $48,000 after acquiring an additional 1,373 shares during the last quarter. Finally, Quarry LP boosted its stake in shares of GRAIL by 1,965.4% during the first quarter. Quarry LP now owns 2,148 shares of the company's stock valued at $55,000 after acquiring an additional 2,044 shares during the last quarter.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该股票的持有。Comerica Bank 在第三季度将其在 GRAIL 的持股比例提高了 59.2%。Comerica Bank 现在拥有 465 股该公司的股票，价值 27,000 美元，此前在上个季度又购买了 173 股。Farther Finance Advisors LLC 在第二季度将其在 GRAIL 的持股比例提高了 768.1%。Farther Finance Advisors LLC 现在拥有 816 股该公司的股票，价值 42,000 美元，此前在上个季度又收购了 722 股。NewEdge Advisors LLC 在第一季度将其在 GRAIL 的持股比例提高了 390.3%。NewEdge Advisors LLC 现在拥有 1760 股该公司的股票，价值 45,000 美元，此前在上个季度又收购了 1401 股。Signaturefd LLC 在第一季度将其在 GRAIL 的持股比例提高了 273.0%。Signaturefd LLC 现在拥有 1876 股该公司的股票，价值 48,000 美元，此前在上个季度又收购了 1373 股。最后，Quarry LP 在第一季度将其在 GRAIL 的持股比例提高了 1965.4%。Quarry LP 现在拥有 2148 股该公司的股票，价值 55,000 美元，此前在上个季度又收购了 2044 股。</p>
</div><h2>GRAIL Company Profile</h2>
<div class="lb-trans"><h2>GRAIL 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.</p>
<div class="lb-trans"><p>GRAIL, Inc 是一家商业阶段的医疗保健公司，专注于开发早期癌症检测技术。它利用机器学习、软件和自动化技术在早期阶段检测和识别多种致命癌症类型。该公司由 Jeffrey T.创立。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than GRAIL</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Why a 20-Second Flight Test Could Unlock Billions for Vertical</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>3 Smart Defensive Stocks for an Uneasy Market</li>
<li>How to Read Stock Charts for Beginners</li>
<li>These 3 Stocks Are Using Buybacks to Signal Market Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 GRAIL 更好</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>为什么 20 秒的飞行测试可能为垂直市场解锁数十亿美元</li>
<li>市值计算器：如何计算市值</li>
<li>3 只适合不安市场的防御性股票</li>
<li>初学者如何阅读股票图表</li>
<li>这 3 只股票正在利用回购来传达市场信心</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GRAIL Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 GRAIL 吗？</h2>
</div><p>Before you consider GRAIL, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 GRAIL 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 GRAIL 并不在名单上。</p>
</div><p>While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GRAIL 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看五只股票</p>
</div>

GRAIL（NASDAQ 代码：GRAL）股价跳空下跌 - 以下是发生的情况